Department of Medicine, Division of Rheumatology and Immunology, Omaha Veterans Affairs Medical Center and University of Nebraska Medical Center, Omaha, NE, USA.
J Rheumatol. 2011 Dec;38(12):2509-16. doi: 10.3899/jrheum.110378. Epub 2011 Sep 15.
Soluble CD14 (sCD14) is involved in innate immune responses and has been implicated to play a pathogenic role in inflammatory diseases including rheumatoid arthritis (RA). No studies have identified the specific factors that influence sCD14 expression in RA. We used cross-sectional data to evaluate the relationship of sCD14 concentrations in RA with measures of disease activity and severity. We hypothesized that sCD14 concentrations would be elevated in subjects with greater RA disease severity and markers of disease activity, compared to subjects with lower disease activity. We also examined whether well-defined polymorphisms in CD14 are associated with sCD14 expression in RA.
Soluble CD14 concentrations were measured using banked serum from patients with RA (n = 1270) and controls (n = 186). Associations of patient factors including demographics, measures of RA disease activity/severity, and select CD14 single-nucleotide polymorphisms (SNP) with sCD14 concentration were examined in patients with RA using ordinal logistic regression.
Circulating concentrations of sCD14 were higher in patients with RA compared to controls (p < 0.0001). Factors significantly and independently associated with higher sCD14 levels in patients with RA included older age, being white (vs African American), lower body mass index, elevated high sensitivity C-reactive protein, and higher levels of disease activity based on the Disease Activity Score (DAS28). There were no significant associations of CD14 tagging SNP with sCD14 level in either univariate or multivariable analyses.
Circulating levels of sCD14 are increased in RA and are highest in patients with increased levels of RA disease activity. In the context of RA, sCD14 concentrations also appear to be strongly influenced by specific patient factors including older age and race but not by genetic variation in CD14.
可溶性 CD14（sCD14）参与固有免疫反应，并被认为在包括类风湿关节炎（RA）在内的炎症性疾病中发挥致病作用。目前尚无研究确定影响 RA 中 sCD14 表达的具体因素。我们使用横断面数据评估 RA 患者 sCD14 浓度与疾病活动度和严重程度测量值之间的关系。我们假设与疾病活动度较低的患者相比，RA 疾病严重程度和疾病活动标志物较高的患者 sCD14 浓度会升高。我们还检查了 CD14 中的明确多态性是否与 RA 中的 sCD14 表达相关。
使用来自 RA 患者（n=1270）和对照者（n=186）的银行血清测量可溶性 CD14 浓度。使用有序逻辑回归分析 RA 患者的患者因素（包括人口统计学、RA 疾病活动/严重程度测量值和选择的 CD14 单核苷酸多态性（SNP））与 sCD14 浓度的关联。
与对照者相比，RA 患者的循环 sCD14 浓度更高（p<0.0001）。与 RA 患者 sCD14 水平较高显著相关的因素包括年龄较大、为白人（而非非裔美国人）、较低的体重指数、较高的高敏 C 反应蛋白和基于疾病活动评分（DAS28）的更高疾病活动水平。在单变量或多变量分析中，CD14 标记 SNP 与 sCD14 水平均无显著相关性。
RA 患者的循环 sCD14 水平升高，且在 RA 疾病活动度增加的患者中最高。在 RA 背景下，sCD14 浓度似乎也受到特定患者因素的强烈影响，包括年龄较大和种族，但不受 CD14 遗传变异的影响。
